Psychopharmacology of Attention Deficit Disorder: Pharmacokinetic, Neuroendocrine, and Behavioral Measures Following Acute and Chronic Treatment with Methylphenidate

14 boys with attention deficit disorder (ADD) ranging in age from 7 to 12 years (mean 10.4 years) for acute studies, and another group of children with ADD receiving methylphenidate chronically.

Methylphenidate (MPH) oral administration at doses of 0.34 mg/kg and 0.65 mg/kg.

Pharmacokinetics of MPH (peak plasma concentration, half-life, AUC) and effects on growth hormone and prolactin.surrogate